Curium has agreed to buy radiopharmaceutical company Lantheus Holdings in a deal worth up to $8 billion, the companies said on Monday.
Deal Details
Under the agreement, Lantheus shareholders will get $102.50 per share in cash when the deal closes, plus rights to receive up to $12 more per share if certain sales targets are met by 2030.
The total consideration of up to $114.50 per share represents a premium of about 14.9% to Lantheus’ last closing price of $99.64.
“We believe this transaction is the ultimate validation of what the Lantheus team has built over seven decades of innovation in radiopharmaceuticals,” said Lantheus CEO Mary Anne Heino.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.